☰

Sonya J. Snedecor, Ph.D. - Publications

Affiliations: 
2002 University of California, Los Angeles, Los Angeles, CA 
Area:
Biostatistics Biology, Immunology
Tree Info Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Schultz BG, Diakite I, Carter JA, Snedecor SJ, Turpin R. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis. Journal of Managed Care & Specialty Pharmacy. 27: 1592-1600. PMID 34714104 DOI: 10.18553/jmcp.2021.27.11.1592  0.306
2020 Schultz R, Diakite I, Carter JA, Snedecor S, Turpin RS. Su1813 COST-EFFECTIVENESS OF VEDOLIZUMAB IV VERSUS ADALIMUMAB SC FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS Gastroenterology. 158: S-658. DOI: 10.1016/S0016-5085(20)32341-6  0.302
2019 Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. Bmc Infectious Diseases. 19: 484. PMID 31146698 DOI: 10.1186/S12879-019-3975-6  0.325
2016 Ektare V, Fox CP, Taylor RS, Timothy IJ, Pena GE, Maher JC, Snedecor SJ. Attainment of Complete Remission Is Significantly Associated with Longer Survival Outcomes in Relapsed/Refractory (R/R) CLL: A Meta-Analysis Blood. 128: 2045-2045. DOI: 10.1182/Blood.V128.22.2045.2045  0.318
2015 McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. The Ocular Surface. PMID 26733111 DOI: 10.1016/J.Jtos.2015.11.002  0.322
2015 Qin L, Luo X, Zou KH, Snedecor SJ. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in vulnerable elderly population in the United States. Journal of Medical Economics. 1-25. PMID 26488196 DOI: 10.3111/13696998.2015.1111893  0.314
2015 Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. British Journal of Haematology. PMID 25907897 DOI: 10.1111/Bjh.13463  0.301
2015 Mahon F, Tran-Duy A, Ocampo RG, Ray D, Mendelson E, Buchbinder A, Edrich P, Snedecor SJ, Saglio G. Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model Blood. 126: 5154-5154. DOI: 10.1182/Blood.V126.23.5154.5154  0.364
2015 Saglio G, Snedecor SJ, Ji X, Tai M, Ray D, Mendelson E, Buchbinder A, Edrich P, Mahon F. Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase Blood. 126: 1579-1579. DOI: 10.1182/Blood.V126.23.1579.1579  0.366
2015 Snedecor SJ, Howlett C, Mato A. Synthesis Of Multiple Types Of Survival Data Within A Weibull Proportional Hazards Meta-Analysis: Treatment Outcomes In Patients With Double Hit Lymphoma (DHL) Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.034  0.304
2014 Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. Plos One. 9: e105653. PMID 25188312 DOI: 10.1371/Journal.Pone.0105653  0.366
2014 Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, Chambers R, Craig C, Stephens J. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. Aids Research and Human Retroviruses. 30: 753-68. PMID 24925216 DOI: 10.1089/Aid.2013.0262  0.322
2014 Solem CT, Snedecor SJ, Khachatryan A, Nedrow K, Tawadrous M, Chambers R, Haider S, Simpson K. Cost of treatment in a US commercially insured, HIV-1-infected population. Plos One. 9: e98152. PMID 24866200 DOI: 10.1371/Journal.Pone.0098152  0.344
2014 Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundhwala Y, Botteman M. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. International Journal of Clinical Practice. 68: 900-18. PMID 24698515 DOI: 10.1111/Ijcp.12411  0.33
2014 Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Practice : the Official Journal of World Institute of Pain. 14: 167-84. PMID 23534696 DOI: 10.1111/Papr.12054  0.329
2014 Howlett C, Landsburg DJ, Chong EA, Snedecor SJ, Schuster SJ, Green TM, Cohen JB, Svoboda J, Nasta SD, Feldman T, Rago A, Land D, Walsh KM, Goy A, Mato AR. Front-Line, Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 Patients (Pts) with Double-Hit Lymphomas (DHL): A Systematic Review and Meta-Analysis Blood. 124: 3056-3056. DOI: 10.1182/Blood.V124.21.3056.3056  0.321
2013 Snedecor SJ, Khachatryan A, Nedrow K, Chambers R, Li C, Haider S, Stephens J. The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients. Plos One. 8: e72784. PMID 23991151 DOI: 10.1371/Journal.Pone.0072784  0.339
2013 Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Desai P, Jalundhwala YJ, Botteman M. Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. Journal of Pain Research. 6: 539-47. PMID 23874121 DOI: 10.2147/Jpr.S45966  0.334
2013 Snedecor SJ, Carter JA, Kaura S, Botteman MF. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. Journal of Medical Economics. 16: 19-29. PMID 22870908 DOI: 10.3111/13696998.2012.719054  0.367
2012 Snedecor SJ, Carter JA, Kaura S, Botteman MF. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. Clinical Therapeutics. 34: 1334-49. PMID 22578308 DOI: 10.1016/J.Clinthera.2012.04.008  0.373
2012 Botteman M, Carter JA, Fishman P, Chandiwana D, Bains M, Snedecor SJ. Cost-effectiveness of denosumab (D) versus zoledronic acid (Z) for skeletal-related event (SRE) reduction in bone-metastatic prostate cancer (mPC) in the United Kingdom. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15189  0.35
2012 Snedecor SJ, Ji X, Magestro M, Stein AM, Botteman M. Estimating Long-Term Life Expectancy in Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results of A Microsimulation Model Blood. 120: 4441-4441. DOI: 10.1182/Blood.V120.21.4441.4441  0.359
2011 Snedecor SJ, Carter JA, Kaura S, Botteman M. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4581. PMID 28023303 DOI: 10.1200/Jco.2011.29.15_Suppl.4581  0.371
2011 Botteman M, Stephens J, Snedecor SJ, Ji X, Hussein M, Coombs J. Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6570. PMID 28020149 DOI: 10.1200/Jco.2011.29.15_Suppl.6570  0.304
2011 Ovanfors A, Stephens J, Snedecor SJ, Patel D, Ji X, Carpiuc KT, Coombs J, Botteman M. Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6572. PMID 28020148 DOI: 10.1200/Jco.2011.29.15_Suppl.6572  0.332
2011 Carter JA, Snedecor SJ, Kaura S, Botteman M. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 294. PMID 27958037 DOI: 10.1200/Jco.2011.29.27_Suppl.294  0.364
2009 Snedecor SJ, Botteman MF, Bojke C, Schaefer K, Barry N, Pickard AS. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep. 32: 817-24. PMID 19544759 DOI: 10.1093/Sleep/32.6.817  0.386
2008 Kelleher C, Snedecor SJ, Lee R, Najib H, Botteman M, Trocio J. UIJ - Evaluating pharmacologic treatment of overactive bladder: The economic costs and benefits of fesoterodine Urotoday International Journal. 1. DOI: 10.3834/Uij.1939-4810.2008.06.55  0.343
2007 Snedecor S, Botteman M, Schaefer K, Barry N, Rubens R, Pickard A. Pnd28 Comparison Of Four Preference-Based Sf-36/Sf-I2 Algorithms To Evaluate The Cost-Effectiveness Of Treatment For Primary Insomnia With Eszopiclone Value in Health. 10. DOI: 10.1016/S1098-3015(10)65366-1  0.313
2007 Snedecor S, Botteman M, Schaefer K, Barry N, Rubens R, Pickard A. Pnd7 An Analytical Model To Predict The Cost-Effectiveness Of Long-Term Eszopiclone For The Treatment Of Primary Insomnia Value in Health. 10. DOI: 10.1016/S1098-3015(10)65345-4  0.315
2005 Snedecor SJ. Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression. Bulletin of Mathematical Biology. 67: 1315-32. PMID 16005505 DOI: 10.1016/J.Bulm.2005.02.004  0.3
Show low-probability matches.